Alchemia Limited (ASX: ACL) advises that Dr Tracie Ramsdale has tendered her resignation as a Non-executive Director of the Company effective 29 June 2016.
Alchemia Limited (ASX: ACL) announces that effective 11 April 2016, Steve Denaro has resigned as Company Secretary and Melanie Leydin will be appointed as Company Secretary in addition to her role as Chief Financial Officer.
Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the appointment of Mr David Lamm to its Board as Non-Executive Director.
Alchemia Limited, (ASX: ACL) a drug discovery and development company, today announced the appointment of Mr Simon Gennari to its Board as NonExecutive Chairman and the retirement of Mr. Ken Poutakidis as Non-Executive Chairman and member of the board.
Alchemia Limited announces that at today’s General Meeting the Return of Capital Resolution put to Shareholders was passed unanimously on a show of hands.
Alchemia Limited announces that at the 2015 Annual General Meeting Resolution Items put to Shareholders were passed on a show of hands, and the Resolution for the Approval for the Sale of Fondaparinux Intellectual Property was approved by a Poll.
Alchemia Limited today announced that it has entered into a binding term sheet for the sale of the worldwide exclusive intellectual property rights to fondaparinux sodium, its generic anti-coagulant drug, to Dr Reddy's Laboratories.
Alchemia Limited today announces its financial results for the year ended 30 June 2015. The Group ended the 2015 financial year with net tangible assets (excluding deferred tax liabilities which relate to intangible assets) of $11.5 million (2014: $11.3 million).